These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 28739563

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy.
    Kerk N, Drabik A, Luger TA, Schneider SW, Goerge T.
    Br J Dermatol; 2013 Apr; 168(4):898-9. PubMed ID: 23106384
    [No Abstract] [Full Text] [Related]

  • 6. Negative Results, Positive Outcome: A Case of Primary Livedoid Vasculopathy With an Elusive Laboratory Workup.
    Al-Obaidi AD, Sabeeh SK, Mohammed MJ, Othman A, Algburi YA, Hashim HT, Alhatemi AQM, Al Hilali Z, Al-Attabi BRT, Al-Awad A.
    J Investig Med High Impact Case Rep; 2024 Apr; 12():23247096241266090. PubMed ID: 39068597
    [Abstract] [Full Text] [Related]

  • 7. [Livedoid vasculopathy. Pathogenesis, diagnosis and treatment of cutaneous infarction].
    Goerge T.
    Hautarzt; 2011 Aug; 62(8):627-34; quiz 635. PubMed ID: 21786003
    [Abstract] [Full Text] [Related]

  • 8. Dabigatran in the management of livedoid vasculopathy.
    Sawada T, Suehiro M.
    Clin Exp Dermatol; 2017 Mar; 42(2):237-239. PubMed ID: 28052437
    [No Abstract] [Full Text] [Related]

  • 9. Prevention of recurrent ulceration of livedoid vasculopathy with long-term apixaban monotherapy.
    Osada SI, Ishikawa N, Hasunuma N, Manabe M.
    J Dermatol; 2019 Apr; 46(4):e142-e143. PubMed ID: 30156315
    [No Abstract] [Full Text] [Related]

  • 10. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
    Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J, Eveslage M, Drabik A, Goerge T.
    Lancet Haematol; 2016 Feb; 3(2):e72-9. PubMed ID: 26853646
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
    Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J, Eveslage M, Drabik A, Goerge T.
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1784-1791. PubMed ID: 31009111
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Livedoid vasculopathy with underlying subcutaneous necrotizing venulitis in an asymptomatic hepatitis B virus carrier: is livedoid vasculopathy a true nonvasculitic disorder?
    Ishibashi M, Miyamoto J, Nagasaka T, Chen KR.
    Am J Dermatopathol; 2009 May; 31(3):293-6. PubMed ID: 19384073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.